Sabrina Correa da Costa, MD* Addiction Psychiatry Fellow Department of Psychiatry Yale University School of Medicine New Haven, Connecticut
Marsal Sanches, MD, PhD, FAPA Associate Professor Research Track Residency Training Director Department of Psychiatry and Behavioral Sciences The University of Texas Health Science Center at Houston McGovern Medical School Houston, Texas
Jair C. Soares, MD, PhD Professor & Chairman Pat R. Rutherford, Jr. Chair in Psychiatry Director, Center of Excellence on Mood Disorders Executive Director UTHealth HCPC Department of Psychiatry and Behavioral Sciences The University of Texas Health Science Center at Houston McGovern Medical School Houston, Texas
*At the time this article was written, Dr. da Costa was Chief Resident, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas.
Disclosures Dr. Soares receives grant or research support from Compass, Pathways, Alkermes, Allergan, Merck, and Pfizer, is a consultant to Johnson & Johnson, Myriad, and LivaNova, and is a speaker for Sanofi and Sunovion. Dr. Soares is an Editorial Consultant for Current Psychiatry. Drs. da Costa and Sanches report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.
Several factors might make clinicians reluctant to diagnose BPD, or bias them to diagnose BD more frequently. These include a lack of familiarity with the diagnostic criteria for BPD, the phenotypical resemblance between BP and BPD, or even concerns about the stigma and negative implications that are associated with a BPD diagnosis.32,37,38
Whereas BD is currently perceived as a condition with a strong biological basis, there are considerable misconceptions regarding BPD and its nature.4-6,22,26 As a consequence, individuals with BPD tend to be perceived as “difficult-to-treat,” “uncooperative,” or “attention-seeking.” These misconceptions may result in poor clinician-patient relationships, unmet clinical and psychiatric needs, and frustration for both clinicians and patients.37
Through advances in biological psychiatry, precision medicine may someday be a part of psychiatric practice. Biological “signatures” may eventually help clinicians in diagnosing and treating psychiatric disorders. Presently, however, rigorous history-taking and comprehensive clinical assessments are still the most powerful tools a clinician can use to accomplish these goals. Finally, destigmatizing psychiatric disorders and educating patients and clinicians are also critical to improving clinical outcomes and promoting mental health in a compassionate and empathetic fashion.
Bottom Line
Despite the phenotypical resemblance between bipolar disorder (BP) and borderline personality disorder (BPD), the 2 are independent conditions with distinct neurobiological and psychopathological underpinnings. Clinicians can use a rigorous assessment of pathological personality traits and characterization of symptoms, such as onset patterns, clinical course, and phenomenology, to properly distinguish between BP and BPD.